Ryckelynck J P, Vergnaud M, Hurault de Ligny B, Allouche G, Malbruny B, Morel C
Pathol Biol (Paris). 1986 May;34(5):328-31.
Peritonitis is the most frequent complication in patients under continuous ambulatory peritoneal dialysis. Intraperitoneal administration of ceftazidime in a dose of 125 mg per liter dialysate achieved serum concentrations higher than the minimal inhibitory concentrations of most organisms in spite of low peritoneal clearance. Serum concentration was stable up to the 120th hour. Dialysate osmolarity had no influence on serum concentration, peritoneal absorption or clearance of ceftazidime. Peritoneal inflammation did not cause changes in ceftazidime pharmacokinetics. Ceftazidime used alone as the first choice treatment was successful in 85%, of cases.
腹膜炎是持续性非卧床腹膜透析患者最常见的并发症。尽管腹膜清除率较低，但每升透析液腹腔内给予125mg头孢他啶可使血清浓度高于大多数微生物的最低抑菌浓度。血清浓度在第120小时前保持稳定。透析液渗透压对头孢他啶的血清浓度、腹膜吸收或清除没有影响。腹膜炎症并未引起头孢他啶药代动力学的改变。单独使用头孢他啶作为首选治疗方法，85%的病例取得了成功。
